Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-21
2006-11-21
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S407000, C549S401000
Reexamination Certificate
active
07138430
ABSTRACT:
The invention describes novel nitrosated and/or nitrosylated nebivolol, novel nitrosated and/or nitrosylated metabolites of nebivolol and novel compositions comprising at least one nitrosated and/or nitrosylated nebivolol and/or at least one nitrosated and/or nitrosylated metabolite of nebivolol, and, optionally, at least one nitric oxide donor and/or at least one antioxidant or a pharmaceutically acceptable salt thereof, and/or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and/or at least one nitrosated compound used to treat cardiovascular diseases. The invention also provides novel compositions comprising nebivolol and/or at least one metabolite of nebivolol and at least one nitric oxide donor, and, optionally, at least one antioxidant or a pharmaceutically acceptable salt thereof, and/or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and/or at least one nitrosated compound used to treat cardiovascular diseases. The compounds and compositions of the invention can also be bound to a matrix. The nitric oxide donor is a compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating and/or preventing vascular diseases characterized by nitric oxide insufficiency; and for treating and/or preventing Raynaud's syndrome; and for treating and/or preventing cardiovascular diseases or disorders.
REFERENCES:
patent: 4654362 (1987-03-01), Van Lommen et al.
patent: 5759580 (1998-06-01), Jans et al.
patent: 5874461 (1999-02-01), de Chaffoy de Courcelles et al.
patent: 6075046 (2000-06-01), De Chaffoy . . .
patent: 6635273 (2003-10-01), Loscalzo et al.
patent: WO 95/22325 (1995-08-01), None
patent: WO 96/19987 (1996-07-01), None
patent: WO 98/21193 (1998-05-01), None
patent: WO 99/00361 (1999-01-01), None
patent: WO 99/67231 (1999-12-01), None
patent: WO-00/49993 (2000-08-01), None
patent: WO 00/51988 (2000-08-01), None
patent: WO-00/51978 (2000-09-01), None
patent: WO 00/61537 (2000-10-01), None
patent: WO 00/61541 (2000-10-01), None
patent: WO 00/61549 (2000-10-01), None
patent: WO-00/67754 (2000-11-01), None
patent: WO 01/12584 (2001-02-01), None
patent: WO 02/051385 (2002-07-01), None
patent: 2005/053685 (2005-06-01), None
patent: 2005/054218 (2005-06-01), None
Jun. 5, 2003. International Search Report for PCT/US02/13667.
Kakoki, Masao et al. Jan. 1999. “Effects of Vasodilatory β-Adrenoceptor Antagonists on Endothelium-Derived Nitric Oxide Release in Rat Kidney.”Hypertension. vol. 33, part II. pp. 467-471.
Brehm, B. R. et al. 2001. “Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells.”Cardiovascular Research. vol. 49. pp. 430-439.
Sep. 7, 2004. Supplementary European Search Report from European Patent Application No. 02766876.3.
Aulakh Charanjit S.
NitroMed Inc.
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Nitrosated and nitrosylated nebivolol and its metabolites,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrosated and nitrosylated nebivolol and its metabolites,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrosated and nitrosylated nebivolol and its metabolites,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3681474